Telix shares jump as FY25 revenue rockets past guidance
Make us a preferred source
Make us a preferred source on Google
The news: Shares in Telix Pharmaceuticals advanced in early trade on the ASX after the biopharmaceutical company said it expected to exceed its full-year revenue guidance.
The numbers: Telix shares were up 6.1% to $25.49 by 10:40am AEDT, extending gains of nearly 140% over the last 12 months.
The dual-listed company reported total unaudited revenue of $783 million for the 2024 financial year, exceeding guidance of $745 million to $776 million, and marking a 55% increase compared to the prior year.
The context: Telix said that strong sales of its prostate cancer diagnostic agent Illuccix helped the company top its full-year revenue guidance.
The Melbourne-based group's revenue is generated predominantly from Illuccix sales, which is currently available in the US, Australia, New Zealand and Canada.
Germany's drugs and medical devices regulator is set to provide its decision on Telix's EU marketing authorisation for Illuccix on Wednesday. The UK's regulator is due to make an approval decision later this month, with a regulatory decision in Brazil expected "imminently".
What they said: "We are well-positioned for significant expansion, including planned launches of multiple imaging products in key markets and advancing late-stage therapeutic assets in pivotal trials," said Telix managing director and group chief executive Christian Behrenbruch.
"2025 is shaping up to be [a] transformative year for Telix."
The source: ASX announcement
